Phillip Samayoa

Since joining Generation Bio in 2017, Phillip has provided operational and strategic leadership across exploratory research, portfolio strategy, and business development. Phillip was a principal at Atlas Venture, where he focused on building novel platform therapeutics companies and was a co-founder of Generation Bio and Dyne Therapeutics and a board observer for HotSpot Therapeutics. Phillip was previously director of MRL Ventures Fund at Merck, where he worked to construct the strategic fund and led investments in early stage therapeutics technologies, including Alector, Translate Bio, and Spero Therapeutics. Prior to that, Phillip was an associate at Flagship Pioneering, where he was involved in building several start-ups, including Codiak BioSciences and Indigo Ag. Phillip graduated from Massachusetts Institute of Technology with dual Bachelor of Science degrees in biological engineering and physics and earned his doctorate in systems biology from University of California San Diego, where he was a National Science Foundation graduate research fellow.